Quest Diagnostics Incorporated

NYSE:DGX

Medical - Diagnostics & Research

Healthcare
$259.69 -1.72%

-$3.41 today

Market cap
$28.57B
Beta
0.59
P/E (TTM)
20.9
EPS (TTM)
$9.31
Dividend yield
1.68%
52W Low $164.65High $213.50

Volume 1.30M

Average 0.91M

DGX Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Quest Diagnostics IncorporatedNYSE: DGX

Net Change in Cash · Q3 FY2026 · quarter ended Sep 2026

Net change in cash growth accelerates

Q3 FY2026 net change in cash of $467M rose 313.3% year over year, ahead of the +209.9% change in trailing-twelve-month net change in cash. Over 3 fiscal years it compounded at -38.6% a year.

Context

  • Net change in cash amounted to 1.2% of revenue in FY2025, down 0.2 pp from a year earlier.
  • Net change in cash increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +313.3% holds above the trailing-twelve-month pace of +209.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$467M+841.3% QoQ
Last fiscal yearDec 2025
-$129M-5.8% YoY
LTMSep 2026
$365M+209.9% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+313.3%——
1 year-5.8%——
3-year CAGR-38.6%——
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
(129M) USD
Year-over-year change
+5.8%

Net Change in Cash vs competitors

How DGX compares with its peers on the latest reported figures

  • DGX's LTM Sep 2026 net change in cash of $365M is the 3rd largest of the 9 companies compared; the peer median is $32.58M.
  • Its year-over-year change of +209.9% is the 3rd highest of 9, against a peer median of -68.8%.
  • Net change in cash amounts to 3.1% of revenue for DGX, versus a peer median of 2.9%.
DGX Competitors Peer median
Net Change in Cash for DGX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LHLabcorp Holdings Inc.LTM Jun 2026$505.5M -232.3%-1.8%3.5%
GHGuardant Health, Inc.LTM Sep 2026$456.49M +39698.6%-26.3%35.7%
DGXQuest Diagnostics IncorporatedLTM Sep 2026$365M +209.9%-38.6%3.1%
ILMNIllumina, Inc.LTM Jun 2026$106M +657.1%-28.0%2.4%
NTRANatera, Inc.LTM Jun 2026$91.48M -55.0%-30.1%3.4%
GRALGRAIL, Inc.LTM Jun 2026$68.16M -91.8%+24.8%41.2%
RDNTRadNet, Inc.LTM Sep 2026$54.11M -197.0%—2.3%
QGENQiagen N.V.LTM Jun 2026$34.69M -82.7%—1.7%
RVTYRevvity, Inc.LTM Jul 2026$30.47M +111.9%+18.1%1.0%
Peer median (excluding DGX) $32.58M-68.8%-14.1%2.9%

Competitors are the stored peer set for DGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income2.08B1.02B908M921M1.05B
Depreciation & Amortization408M437M439M493M570M
Deferred Income Tax(57M)1M(49M)13M105M
Stock-Based Compensation79M77M77M88M88M
Change in Working Capital87M119M(145M)(201M)50M
Accounts Receivables81M246M(15M)(71M)(106M)
Inventory(20M)0000
Accounts Payables35M(149M)(55M)(67M)129M
Other Working Capital(9M)22M(75M)(63M)27M
Other Non-Cash Items(364M)69M42M20M27M
Operating Cash Flow2.23B1.72B1.27B1.33B1.89B
Capital Expenditures(403M)(404M)(408M)(425M)(527M)
Acquisitions (Net)424M(144M)(611M)(2.16B)(101M)
Purchases of Investments(3M)(5M)000
Sales of Investments403M5M000
Other Investing Activities(400M)5M(42M)41M(3M)
Investing Cash Flow21M(543M)(1.06B)(2.55B)(631M)
Debt Repayment(2M)(2M)748M1.54B(602M)
Common Stock Issued000079M
Common Stock Repurchased(2.2B)(1.41B)(275M)(151M)(450M)
Dividends Paid(309M)(305M)(314M)(331M)(353M)
Other Financing Activities(30M)(17M)1M23M(62M)
Financing Cash Flow(2.54B)(1.73B)160M1.08B(1.39B)
Effect of Forex Changes000(7M)4M
Net Change in Cash(286M)(557M)371M(137M)(129M)
Free Cash Flow1.83B1.31B864M909M1.36B

Quest Diagnostics Incorporated

NYSE:DGX

Intrinsic Alpha fair value

Locked

Current Price

$259.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.